Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of April 2025, with a specific reporting date of April 14, 2025. The filing primarily announces a new capital raise and updates on an existing financing facility.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data for the period. The only specific financial metric disclosed is the gross proceeds from a new financing event.
- Registered Direct Offering Proceeds: $3 million (gross proceeds upon closing).
- ATM Facility Status: Maximum aggregate offering price reduced to zero.
- ADS Sold under ATM: 1,423,612 ADS offered or sold to date.
Material Changes
The primary material change is the execution of definitive agreements for a registered direct offering. Additionally, the Company terminated its existing At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC, reducing the remaining capacity to zero.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on operational outlook, or specific risk factors beyond the standard incorporation of the press release. The reduction of the ATM facility to zero indicates a strategic shift in capital raising methods, though the filing does not explicitly detail the rationale or future liquidity strategy beyond the immediate $3 million raise.
Investor Verification Checklist
- Verify the closing date and actual net proceeds of the $3 million registered direct offering.
- Confirm the dilution impact of the new offering on existing shareholders.
- Review the attached press release (Exhibit 99.1) for details on the use of proceeds.
- Assess the Company's current cash runway given the termination of the ATM facility.